EnVVeno Medical Corporation (NASDAQ:NVNO) | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

BRIEF

published on 11/20/2024 at 14:35, 20 hours 4 minutes ago

EnVVeno Medical Unveils One-Year VenoValve Trial Results

Clinical Trial VenoValve Health Outcomes FDA Application CVI Treatment
PRESS RELEASE

published on 11/20/2024 at 14:30, 20 hours 9 minutes ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
enVVeno Medical presents one-year data on VenoValve U.S. pivotal trial at VEITH Symposium supporting FDA pre-market authorization application. Study shows significant clinical benefits and safety profile

EnVVeno Medical VenoValve FDA Application Pivotal Trial VEITH Symposium
BRIEF

published on 11/19/2024 at 14:20, 1 day 20 hours ago

EnVVeno Medical Seeks FDA Approval for VenoValve

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency PMA Application
PRESS RELEASE

published on 11/19/2024 at 14:15, 1 day 20 hours ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
enVVeno to present definitive one year data from PMA application at 51st VEITH Symposium. Company aims for FDA approval to market VenoValve in the US

FDA Approval VenoValve CVI PMA Application EnVVeno
BRIEF

published on 10/31/2024 at 13:40, 20 days 20 hours ago

EnVVeno Medical's Q3 2024 Financials and Upcoming FDA Milestones

Financial Results FDA Approval Clinical Trials VenoValve EnVVe Progress
PRESS RELEASE

published on 10/31/2024 at 13:35, 20 days 21 hours ago

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
enVVeno Medical Corporation reports progress towards FDA PMA approval for VenoValve and enVVe transcatheter-based valve replacement. Company ends quarter with $48.4M cash

Financial Results VenoValve Clinical Program FDA PMA Approval EnVVe Transcatheter Valve
BRIEF

published on 10/28/2024 at 13:35, 23 days 21 hours ago

EnVVeno Medical Commences Pre-Clinical Study for enVVe Valve

FDA Approval EnVVeno Medical CVI Treatment GLP Study EnVVe Valve
PRESS RELEASE

published on 10/28/2024 at 13:30, 23 days 21 hours ago

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
enVVeno Medical Corporation successfully completes first wave of implants with updated delivery system for enVVe replacement venous valve, on track for U.S. pivotal trial in mid-2025

EnVVeno Medical Corporation Venous Disease Implants EnVVe Pivotal Trial
BRIEF

published on 09/27/2024 at 03:23, 1 month 24 days ago

EnVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

Public Offering EnVVeno Medical VenoValve Venous Disease Titan Partners Group
PRESS RELEASE

published on 09/27/2024 at 03:18, 1 month 24 days ago

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
enVVeno Medical Corporation announces pricing of underwritten public offering for the treatment of venous disease. Offering led by Titan Partners Group. Expected gross proceeds of $15.0 million

Public Offering Gross Proceeds EnVVeno Medical Corporation Venous Disease Titan Partners Group

1 2 ... 5

Accesswire

Published on 11/21/2024 at 10:03, 36 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 39 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 39 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 4 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 14 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 34 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 36 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 39 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 39 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 38 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 19 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 54 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 54 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE